These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 26867651

  • 21. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
    Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E.
    Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
    [Abstract] [Full Text] [Related]

  • 22. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y, Zeng JC, Yin F, Zhang CL, Zhang Y, Li SX, Liu X, Zhang C, Xue QY, Lin H, Pei FX.
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [Abstract] [Full Text] [Related]

  • 23. Acute blepharitis: an unusual complication of zoledronic acid.
    Osta LE, Osta BE.
    Int J Rheum Dis; 2017 Apr; 20(4):515-518. PubMed ID: 26412501
    [No Abstract] [Full Text] [Related]

  • 24. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis.
    Kulkarni P, Cushman T, Donthireddy V, Rao S.
    BMJ Case Rep; 2016 Feb 03; 2016():. PubMed ID: 26843222
    [Abstract] [Full Text] [Related]

  • 29. Bisphosphonate-associated orbital inflammation--a case report and review.
    Peterson JD, Bedrossian EH.
    Orbit; 2012 Apr 03; 31(2):119-23. PubMed ID: 22489855
    [Abstract] [Full Text] [Related]

  • 30. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K.
    Osteoporos Int; 2017 Jun 03; 28(6):1995-2002. PubMed ID: 28299378
    [Abstract] [Full Text] [Related]

  • 31. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy.
    Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M.
    Joint Bone Spine; 2017 Mar 03; 84(2):213-215. PubMed ID: 27939801
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M, Bultink IE, Dijkmans BA, Lems WF.
    Osteoporos Int; 2005 Nov 03; 16(11):1432-5. PubMed ID: 15883662
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
    Lee CY, Suzuki JB.
    Implant Dent; 2015 Apr 03; 24(2):227-31. PubMed ID: 25734948
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.